Walleye Capital’s C4 Therapeutics CCCC Stock Holding History

Walleye Capital’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.05K	Sell	400 -24,500	-98%	-$57.7K	﹤0.01%	4262
2025 Q4	$47.6K	Buy	24,900 +400	+2%	+$948	﹤0.01%	4090
2025 Q3	$54.4K	Buy	+24,500	New	+$58.8K	﹤0.01%	3977
2025 Q1	–	Sell	-2,900	Closed	-$10.4K	–	4317
2024 Q4	$10.4K	Buy	+2,900	New	+$14.4K	﹤0.01%	4572
2024 Q3	–	Sell	-21,600	Closed	-$99.8K	–	5334
2024 Q2	$99.8K	Sell	21,600 -12,800	-37%	-$76.3K	﹤0.01%	4716
2024 Q1	$281K	Buy	+34,400	New	+$267K	﹤0.01%	3706
2023 Q2	–	Sell	-4,200	Closed	-$13.2K	–	4364
2023 Q1	$13.2K	Buy	+4,200	New	+$24.7K	﹤0.01%	3488

Other funds holding CCCC

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Walleye Capital's CCCC Position: Q1 2026 in Review

Walleye Capital reduced its C4 Therapeutics (CCCC) stake by 46% in Q1 2026, selling an estimated $481K and leaving 239,118 shares worth $629K. The position accounts for ﹤0.01% of the portfolio, ranked #2478.

Walleye Capital first reported a position in CCCC in Q4 2021 and has held it in 10 quarters since. The position peaked at $2.63M in Q4 2021. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

Walleye Capital held 239,118 shares of C4 Therapeutics worth $629K as of Q1 2026.
Walleye Capital sold 204,223 C4 Therapeutics shares in Q1 2026, an estimated $481K.
C4 Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #2478 holding.
Walleye Capital first reported a position in C4 Therapeutics in Q4 2021 and has held it in 10 quarters since.
Walleye Capital's C4 Therapeutics position peaked at $2.63M in Q4 2021.
123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.